Triple Negative Breast Cancer Pipeline, Clinical Trials, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated)

DelveInsight's, "Triple Negative Breast Cancer Pipeline Insight 2023" report provides comprehensive insights about 75+ Triple Negative Breast Cancer Companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Triple Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Triple Negative Breast Cancer Pipeline Report
• DelveInsight's Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline treatment therapies.
• The leading Triple Negative Breast Cancer Companies working in the market include Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
• Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
• January 2024: TransThera Sciences (Nanjing), Inc. announced a study of Phase 1 clinical trials for TT-00420. This is a first-in-human, phase I clinical research study with TT-00420, an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor micro-environment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors. The study consists of a dose escalation part followed by a MTD expansion part.
• December 2023: Gilead Sciences announced a study of Phase 3 clinical trials for Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel, Gemcitabine, and Carboplatin. The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
• November 2023: Shanghai Jiaolian Drug Research and Development Co., Ltd announced a study of Phase 2 & 3 clinical trials for B013+Nab-Paclitaxel. This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
• November 2023: Gilead Sciences announced a study of Phase 3 clinical trials for Pembrolizumab. The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
• November 2023: AstraZeneca announced a study of Phase 1 & 2 clinical trials for Datopotamab Deruxtecan (Dato-DXd). This is a Phase 1/Phase 2, multicentre, open-label, multiple-cohort study, which is designed to evaluate the efficacy, safety, Pharmacokinetic, and immunogenicity of Dato-DXd in adult Chinese participants with advanced or metastatic solid tumours. It is a single-arm study with no blinding.

Request a sample and discover the recent advances in Triple Negative Breast Cancer Treatment Drugs @ Triple Negative Breast Cancer Infection Pipeline Report- https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Triple Negative Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Triple Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Triple Negative Breast Cancer Overview
Triple Negative Breast Cancer (TNBC) is defined as a tumor where the estrogen and progesterone (ER/PR) are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers.

Find out more about Triple Negative Breast Cancer Treatment Landscape @ Drugs for Triple Negative Breast Cancer Treatment- https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Triple Negative Breast Cancer Emerging Drugs Profile
• Camrelizumab: Jiangsu HengRui Medicine
• IPI-549: Infinity Pharmaceuticals
• PMD-026: Phoenix Molecular Designs

Triple Negative Breast Cancer Pipeline Therapeutics Assessment
There are approx. 75+ Triple Negative Breast Cancer Companies which are developing the therapies for Triple Negative Breast Cancer. The Triple Negative Breast Cancer companies which have their Triple Negative Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Jiangsu HengRui Medicine.

DelveInsight's Triple Negative Breast Cancer pipeline report covers around 80+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Triple Negative Breast Cancer Pipeline Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Triple Negative Breast Cancer Pipeline Therapies @ Triple Negative Breast Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Triple Negative Breast Cancer Pipeline Report
• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Triple Negative Breast Cancer Companies- Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
• Triple Negative Breast Cancer Pipeline Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.

Dive deep into rich insights for new drugs for Triple Negative Breast Cancer treatment, Visit @ Triple Negative Breast Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Triple Negative Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Triple Negative Breast Cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Camrelizumab: Jiangsu HengRui Medicine
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. IPI-549: Infinity Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. PMD-026: Phoenix Molecular Designs
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Triple Negative Breast Cancer Key Companies
18. Triple Negative Breast Cancer Key Products
19. Triple Negative Breast Cancer- Unmet Needs
20. Triple Negative Breast Cancer- Market Drivers and Barriers
21. Triple Negative Breast Cancer- Future Perspectives and Conclusion
22. Triple Negative Breast Cancer Analyst Views
23. Triple Negative Breast Cancer Key Companies
24. Appendix

For further information on the Triple Negative Breast Cancer pipeline therapeutics, reach out @ Triple Negative Breast Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Published Links-

https://forum.eset.com/profile/88964-denny-dones/?tab=field_core_pfield_11
https://en.pinkoi.com/user/gg_116344212900924579142
https://dennydones9.diary.ru/
https://slideslive.com/ewkwsgtt7o?tab=about
https://dennydones.substack.com/p/behcets-syndrome-market-size-in-the?r=33xju7&utm_campaign=post&utm_medium=web
https://scocial-online.mn.co/posts/46864423
https://akb.tribe.so/post/behcet-s-disease-a-rare-and-chronic-inflammatory-condition-has-long-posed-c--6576dd3288d020256754898b
https://www.sutori.com/en/denny-dones?tab=profile
https://network-96590.mn.co/posts/46865392
https://lean-in-bay-area.mn.co/posts/46865790
https://network-88594.mn.co/posts/46865905
https://decide.mn.co/posts/46866036
https://jomijomig.mn.co/posts/46866708
https://constantlycheeky.mn.co/posts/46867239
https://www.vwvortex.com/members/ybhardwaj.3957496/#about
https://redline-rp.mn.co/posts/46868784
https://network-1588972.mn.co/posts/advancements-and-challenges-in-the-metastatic-melanoma-market
https://thecircle360.mn.co/posts/47424666
https://togethers.mn.co/posts/47424994
https://moneyschoolinc.mn.co/posts/47425167
https://renaissance.mn.co/posts/47425340
https://www.gamemaps.com/profile/1258006
https://presenceofeden.mn.co/posts/47426181
https://thecleverbeaver.mn.co/posts/47426376
https://network-1033912.mn.co/posts/47426607
https://music-producers.mn.co/posts/47426714
https://healingtheinnerme.mn.co/posts/47426814
https://caribbeanonelove.mn.co/posts/47427255
https://ultrasbook.mn.co/posts/47427170
https://voz.vn/u/dennydones99.1954229/#about
https://www.avsforum.com/members/dennydones99.9714847/#about
https://club-elixir.mn.co/posts/47495566
https://ceo-codes.mn.co/posts/47495634
https://skouting.mn.co/posts/47495827
https://network-1311522.mn.co/posts/47495953
https://network-21603.mn.co/posts/47496087
https://jobs.blooloop.com/employers/2614577-delveinsight
https://network-90617.mn.co/posts/47497231
https://www.gn2.poli.ufrj.br/profile/dennydones99/profile
https://vibe-hangout.mn.co/posts/47497589
https://englishclub.mn.co/posts/47497804
https://www.social-vape.com/read-blog/99678
https://hanson.net/users/dennydones99
https://app.scholasticahq.com/scholars/248575-denny-dones
https://credibleleaders.mn.co/posts/47499537
https://network-64869.mn.co/posts/47499548
https://agario-game-org.mn.co/posts/47500134
https://beermapping.com/account/dennydones99
https://caydenbook.mn.co/posts/adeno-associated-virus-vectors-in-gene-therapy-market-size-and-outlook-report-2032
https://rdd-rapter-gameing.mn.co/posts/adeno-associated-virus-vectors-in-gene-therapy-market-outlook-report-2032
https://www.pozible.com/profile/denny-dones
https://www.charitywater.org/denny-dones
https://pologics.mn.co/posts/47645227
https://network-75595.mn.co/posts/47645350
https://futurewear.mn.co/posts/47645511
https://forum.instube.com/u/johnsmithnevadaus9
https://www.pixiv.net/en/users/101730403
https://platform.wegohealth.com/forum/t/monoclonal-gammopathy-of-undetermined-significance-market-insight-epidemiology-and-market-forecast-2032/1175
https://network-483739.mn.co/posts/47647105
https://unplugfromthematrix.mn.co/posts/47647275
https://diy-vision.mn.co/posts/47647380
https://network-6570.mn.co/posts/47647667
https://jobs.thetab.com/employers/1458246-delveinsight
https://careero.mn.co/posts/47652643
https://fromfostercaretoceo.mn.co/posts/47652747
https://www.remotehub.com/denny.dones
https://vibe-3-0.mn.co/posts/monoclonal-gammopathy-of-undetermined-significance-market-insight-epidemiology-and-market-forecast
https://gamingnetwork.mn.co/posts/47654203
https://lgbtgia-chat.mn.co/posts/47654443
https://network-49642.mn.co/posts/47654787
https://vaynernation.mn.co/posts/47708020
https://network-68818.mn.co/posts/47708234
https://network-96638.mn.co/posts/47708353
https://machineintelligence.mn.co/posts/methicillin-resistant-staphylococcus-aureus-market-insight-epidemiology-and-market-forecast-2032
https://www.wpanet.org/profile/ybhardwaj/profile
https://antekk.mn.co/posts/47709117
https://www.noteflight.com/profile/101e63d196889e9ea41b68375ecaa38bf5d46aba
https://roosterteeth.com/g/post/82b171a2-75fb-44d1-8131-6b3628b62658
https://friendsgroup.mn.co/posts/47710599
https://network-30.mn.co/posts/47710918
https://keywebco.mn.co/posts/methicillin-resistant-staphylococcus-aureus-market-size-and-outlook-report-2032
https://network-19115.mn.co/posts/47711333
https://teacher-dot-network.mn.co/members/20931428
https://inclusionbusiness.mn.co/posts/47712828
https://snapped.mn.co/posts/methicillin-resistant-staphylococcus-aureus-market-research-report
https://mylook-online.mn.co/posts/47753600
https://pig-landtin.mn.co/posts/47753674
https://the-e-group-club.mn.co/posts/47754907
https://playeur.com/u/dennydones99
https://profitfirst.mn.co/posts/47757615
https://chatclub.mn.co/posts/47757715
https://visbn.mn.co/posts/advancements-in-perivascular-epithelioid-cell-tumor-market-current-trends-and-future-prospects
https://globalaffairs.mn.co/posts/perivascular-epithelioid-cell-tumor-market-insight-epidemiology-and-market-forecast-2032
https://for-the-dolers.mn.co/posts/47758103
https://click-funnels.mn.co/posts/47763706
https://mt2.org/uyeler/dennydones99.12436/#about
https://blogger-mania.mn.co/posts/47769537
https://kyte-en-espanol.mn.co/posts/47770089
https://network-4526.mn.co/posts/47769942
https://realfirefighters.mn.co/posts/47769768
https://wanneroo-social.mn.co/posts/advancements-in-hydrocephalus-treatment-market-a-comprehensive-overview
https://network-504797.mn.co/posts/47835298
https://tdcommunitynetworks.mn.co/posts/47835354
https://beyondher.mn.co/posts/47835423
https://edunet.mn.co/posts/47835672
https://tbc-coin.mn.co/posts/47835768
https://www.wanikani.com/users/dennydones999
https://cigarbook.mn.co/posts/47841666
https://imgpile.com/dennydones999

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/peripheral-nerve-repair-devices-market

This release was published on openPR.